Q&A: Melissa Paige, UVA Health Systems’ Pharmacy Patient Medication Assistance Principal Coordinator
Monday January 7th, 2019
It is imperative for healthcare organizations to stay on top of the latest information, advancements, and processes related to real-time benefit check. For this reason, we’re excited for you to join us on February 25–26 in Austin for the 2nd Real-Time Benefit Verification and Electronic Prior Authorization Forum. Our faculty of industry experts will be on hand to share actionable insights and content with you — download the brochure to see all of the informative sessions on this year’s program.
Recently, we had the opportunity to chat with one of our speakers — Melissa Paige, Pharmacy Patient Medication Assistance Principal Coordinator, UVA HEALTH SYSTEMS — to discuss her case study session, Current Workflow: ePA Process to Facilitate Faster Patient Access, as well as challenges within the industry.
What are some of the current challenges that you are facing? How are you overcoming the challenges you face?
Access to care for Medicare patients. When a product is launched, it’s a hit or miss knowing if the brand will help out a Medicare patient on a product until we actually go through the process. When you’re 3rd to market, and the other two competitors offer solutions for our Medicare patients we would hope they would try to press this internally as well. Even with some of the manufacturers that cover Medicare D patients for oral oncolytics will not have any options for Medicare Part B patients for their infused or injectable products. At the end of the day, it is financial toxicity that is the deciding factor if a patient will start treatment and adhere to the therapy. When the clinics are inquiring on certain therapies for their patients, we can quickly identify barriers before even pre-authorizing the medication.
What are some key takeaways that you hope attendees will learn from your session?
A large health system is very hard to come up with a standard solution, and it takes multiple stakeholders to buy into any process that’s implemented. It takes more than just a clinic trying to do this on their own to get patients started on treatment. The multiple pathways that a medication can go (co-pay assistance, foundation support or patient assistance) and the multiple terms used and defining who is what, and what form initiates what (HUB form, Patient Assistance Application separate from the HUB form, What is a Field Reimbursement, etc.), this can get very confusing. Having a team specialized on patient access barriers that value the roles and support that manufacturers bring to the table is crucial.
What are you interested in learning more about at this year’s event?
What initiatives are being taken to help RTBC and EPA come into the medical pre-auth discussion? I’d hope to hear additional updates from NCPDP on where we are. I’m excited to hear from another health system on their pathways on getting patients started on treatment.
What are you most looking forward to by attending this year’s event?
I’m looking forward to having an engaged conversation, where attendees can take something away and find this conference valuable.
Don’t miss Melissa’s informative session — reserve your seat today! Please mention Priority Code EM4C, so we know how you heard about this event.
Want to save up to 25% on your registration? Sign up with your colleagues to take advantage of our group rates!
We look forward to seeing you in Austin this February!
Interested in sponsorship and exhibition opportunities? Please contact Dor Peled at email@example.com or 917-258-5159.
From The Blog
- Commercial Strategy
- Content Marketing
- Data Management
- Digital Marketing
- Drug Safety
- Emerging Markets
- ExL Events News
- Medical Devices
- Medical Education
- Meeting Planning
- Patient Engagement
- Public/Government Relations
- Regulatory Affairs